Ashish Kamat, Professor and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, shared on LinkedIn:
“BOND-003 Cohort C data in The Lancet Oncology.
A 75% CR rate at any time, with a median follow-up of 25.8 months and no grade 3/4 treatment-related adverse events, represents an important contribution to the evolving treatment landscape for BCG-unresponsive NMIBC.
Advances like this don’t happen overnight. They are built on patients willing to participate, investigators who believe early, committed clinical teams, and industry partners who stay the course.
Science is a team sport. Congratulations to everyone involved.”
Title: Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
Authors: Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi, Edward M. Uchio, Seung Il Jung, Trinity Bivalacqua, Gary D. Steinberg, Neal D. Shore, James M. Burke, Hiroshi Kitamura.
You can also read ‘RADICAL Trial: Radium-223 Plus Cabozantinib Does Not Improve SSE-FS in mRCC With Bone Metastases‘
